temozolomide has been researched along with Hyperprolactinemia in 3 studies
Hyperprolactinemia: Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal." | 7.78 | Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D, 2012) |
| "We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal." | 3.78 | Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wildemberg, LE | 1 |
| Fialho, C | 1 |
| Gadelha, MR | 1 |
| Bilbao, I | 1 |
| Egaña, N | 1 |
| García, C | 1 |
| Olaizola, I | 1 |
| Philippon, M | 1 |
| Morange, I | 1 |
| Barrie, M | 1 |
| Barlier, A | 1 |
| Taieb, D | 1 |
| Dufour, H | 1 |
| Conte-Devolx, B | 1 |
| Brue, T | 1 |
| Castinetti, F | 1 |
1 review available for temozolomide and Hyperprolactinemia
| Article | Year |
|---|---|
Prolactinomas.
Topics: Antineoplastic Agents, Alkylating; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agon | 2021 |
2 other studies available for temozolomide and Hyperprolactinemia
| Article | Year |
|---|---|
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined | 2017 |
Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
Topics: Adult; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Cranial Irradiation; Dacarbazine | 2012 |